Batavia Biosciences

Batavia Biosciences is a specialized CDMO focused on viral vector and vaccine development and manufacturing, serving biotech and pharma clients globally. The company differentiates itself through proprietary technology platforms like HIP-Vax® and SCOUT, which aim to improve yields, reduce timelines, and lower costs in bioprocessing. With a strong track record of successful GMP runs and a high rate of returning customers, Batavia is positioned as a key partner in advancing novel biologics, particularly for infectious diseases and gene therapies. Its strategic partnerships, such as with VBC and MEVAC for vaccine localization in Africa, underscore its role in strengthening global health supply chains.

Proprietary bioprocessing platforms including HIP-Vax® (fixed-bed bioreactor for vaccine production), SCOUT (high-throughput process development), SATIRN, STEP, and SIDUS, focused on intensifying and streamlining viral vector and vaccine manufacturing.

Batavia competes in a crowded CDMO market against large global players (e.g., Lonza, Catalent) and other specialized viral vector/vaccine CDMOs (e.g., Oxford Biomedica, CEVEC). Its differentiation lies in its niche focus on process intensification technologies like fixed-bed bioreactors and its strategic partnerships for vaccine localization in key geographic regions.